{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:46:10Z","timestamp":1780476370984,"version":"3.54.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vaccine.2015.10.024","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T07:36:50Z","timestamp":1445585810000},"page":"6771-6777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo"],"prefix":"10.1016","volume":"33","author":[{"given":"Esteban","family":"Servat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodrey W.","family":"Ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Cayatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Gemmell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengrong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2015.10.024_bib0130","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1073\/pnas.59.1.94","article-title":"Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis","volume":"59","author":"Henle","year":"1968","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Oct. (3)","key":"10.1016\/j.vaccine.2015.10.024_bib0135","first-page":"76","article-title":"An overview of Epstein\u2013Barr Virus: from discovery to future directions for treatment and prevention","volume":"7","author":"Andersson","year":"2000","journal-title":"Herpes"},{"issue":"Dec. (3)","key":"10.1016\/j.vaccine.2015.10.024_bib0140","first-page":"78","article-title":"Epstein\u2013Barr virus-associated cancers: aetiology and treatment","volume":"10","author":"Lopes","year":"2003","journal-title":"Herpes"},{"issue":"Aug. (4)","key":"10.1016\/j.vaccine.2015.10.024_bib0145","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1034\/j.1399-3046.2002.02029.x","article-title":"Epstein\u2013Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management","volume":"6","author":"Smets","year":"2002","journal-title":"Pediatr Transplant"},{"issue":"Nov. (5)","key":"10.1016\/j.vaccine.2015.10.024_bib0150","first-page":"989","article-title":"Relation between neutralization of Epstein\u2013Barr virus and antibodies to cell-membrane antigens-induced by the virus","volume":"45","author":"Pearson","year":"1970","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.vaccine.2015.10.024_bib0155","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein\u2013Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.024_bib0160","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1073\/pnas.77.9.5307","article-title":"Monoclonal antibodies against the major glycoprotein (gp350\/220) of Epstein\u2013Barr virus neutralize infectivity","volume":"77","author":"Thorley-Lawson","year":"1980","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Aug. (2)","key":"10.1016\/j.vaccine.2015.10.024_bib0165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/JVI.43.2.730-736.1982","article-title":"Identification and isolation of the main component (gp350\u2013gp220) of Epstein\u2013Barr virus responsible for generating neutralizing antibodies in vivo","volume":"43","author":"Thorley-Lawson","year":"1982","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.10.024_bib0170","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev Biol Stand"},{"issue":"Jun. (24)","key":"10.1016\/j.vaccine.2015.10.024_bib0175","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.024_bib0180","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein\u2013Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"issue":"Feb. (Pt 2)","key":"10.1016\/j.vaccine.2015.10.024_bib0185","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1099\/0022-1317-68-2-535","article-title":"Epitope mapping of the major Epstein\u2013Barr virus outer envelope glycoprotein gp350\/220","volume":"68","author":"Qualtiere","year":"1987","journal-title":"J Gen Virol"},{"issue":"Feb. (7\u20138)","key":"10.1016\/j.vaccine.2015.10.024_bib0190","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","article-title":"Expression of Epstein\u2013Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine","volume":"17","author":"Jackman","year":"1999","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2015.10.024_bib0195","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1128\/JVI.62.12.4452-4464.1988","article-title":"Soluble gp350\/220 and deletion mutant glycoproteins block Epstein\u2013Barr virus adsorption to lymphocytes","volume":"62","author":"Tanner","year":"1988","journal-title":"J Virol"},{"issue":"Oct. (2)","key":"10.1016\/j.vaccine.2015.10.024_bib0200","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0042-6822(88)90509-0","article-title":"Antigenic analysis of the Epstein\u2013Barr virus major membrane antigen (gp350\/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine","volume":"166","author":"Emini","year":"1988","journal-title":"Virology"},{"issue":"Nov. (10)","key":"10.1016\/j.vaccine.2015.10.024_bib0205","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.4049\/jimmunol.167.10.5758","article-title":"Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)\/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface","volume":"167","author":"Guthridge","year":"2001","journal-title":"J Immunol"},{"issue":"Sep. (2)","key":"10.1016\/j.vaccine.2015.10.024_bib0210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.virol.2009.06.013","article-title":"Human antibody titers to Epstein\u2013Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay","volume":"391","author":"Sashihara","year":"2009","journal-title":"Virology"},{"issue":"Dec. (23)","key":"10.1016\/j.vaccine.2015.10.024_bib0215","doi-asserted-by":"crossref","first-page":"11162","DOI":"10.1128\/JVI.74.23.11162-11172.2000","article-title":"Epstein\u2013Barr virus that lacks glycoprotein gN is impaired in assembly and infection","volume":"74","author":"Lake","year":"2000","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.024_bib0220","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/glycob\/cwp079","article-title":"Optimal and consistent protein glycosylation in mammalian cell culture","volume":"19","author":"Hossler","year":"2009","journal-title":"Glycobiology"},{"issue":"9","key":"10.1016\/j.vaccine.2015.10.024_bib0225","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/nprot.2007.321","article-title":"The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability","volume":"2","author":"Niesen","year":"2007","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.vaccine.2015.10.024_bib0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","article-title":"Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein\u2013Barr virus infection in university students","volume":"207","author":"Balfour","year":"2013","journal-title":"J Infect Dis"},{"issue":"Jun. (12)","key":"10.1016\/j.vaccine.2015.10.024_bib0235","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/infdis\/jit096","article-title":"Primary Epstein\u2013Barr virus infection: impact of age at acquisition, coinfection, and viral load","volume":"207","author":"Balfour","year":"2013","journal-title":"J Infect Dis"},{"issue":"Nov. (10)","key":"10.1016\/j.vaccine.2015.10.024_bib0240","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1086\/522531","article-title":"Epstein\u2013Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients","volume":"45","author":"Aalto","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Apr. (7)","key":"10.1016\/j.vaccine.2015.10.024_bib0245","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1172\/JCI119315","article-title":"Epstein\u2013Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma","volume":"99","author":"Kersten","year":"1997","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.vaccine.2015.10.024_bib0250","doi-asserted-by":"crossref","first-page":"e1002308","DOI":"10.1371\/journal.ppat.1002308","article-title":"Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge","volume":"7","author":"Sashihara","year":"2011","journal-title":"PLoS Pathog"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15014395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T03:43:36Z","timestamp":1599709416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15014395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":25,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0264410X15014395"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of the critical attribute(s) of EBV gp350 antigen required for elicitation of a neutralizing antibody response in vivo","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}